The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
|Videos|January 9, 2018
Dr. Domchek on Promising Biomarkers in Breast Cancer
Author(s)Susan Domchek, MD
Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.
Advertisement
Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.
Biomarkers such as BRCA1/2 are currently used to determine treatment for patients with breast cancer, explains Domcheck.
Domcheck adds that if a patient is microsatellite instability-high (MSI-H), then that patient can receive pembrolizumab (Keytruda) regardless of tumor site.
Advertisement
Related to this article
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5